In preclinical studies, VBI’s new mRNA-launched eVLP (MLE) technology has demonstrated an ability to generate stronger B- and T-cell signals than those seen with other mRNA vaccines tested.

There were 106 lung transplants performed across the 2021-2022 period in the UK, but more than 200 people remain on the waiting list. Health professionals hope that broader adoption of EVLP ...

VBI Vaccines Inc. has announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology, which expands on the company's current proprietary eVLP technology ...

VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has expanded its collaboration with the ...

Ex vivo lung perfusion (EVLP) is a technique that allows for donor lungs to be maintained, assessed, and potentially reconditioned outside of the body before transplantation.

By Reuters July 19, 201612:55 PM UTCUpdated ago July 19 (Reuters) - VBI Vaccines Inc * VBI Vaccines applies its EVLP platform in development of a novel vaccine candidate to prevent Zika virus ...

In preclinical studies, VBI’s new mRNA-launched eVLP (MLE) technology has demonstrated an ability to generate stronger B- and T-cell signals than those seen with other mRNA vaccines tested.